Allos Therapeutics, Inc. (Nasdaq: ALTH) announced the results from its Phase III study of Efaproxyn™ in patients with brain metastases. Results of the study, which were reported in the Journal of Clinical Oncology, suggest that the addition of Efaproxyn™ to whole brain radiation therapy may improve survival and response rates in patients with brain metastases, [...]